Innovative Medication Shows Promise in Managing Resistant Hypertension and Protecting Kidney Function
A new drug, baxdrostat, shows promise in effectively lowering resistant high blood pressure and protecting kidney health, offering hope for a significant advancement in hypertension and kidney disease treatment.
A groundbreaking medication, baxdrostat, has demonstrated significant potential in lowering blood pressure levels that are difficult to control with standard treatments and may also slow the progression of kidney disease. In a recent stage 2 clinical trial involving nearly 200 participants, baxdrostat not only led to a substantial reduction in blood pressure but also showed promising effects on kidney health. Participants treated with baxdrostat exhibited less than half the amount of urinary albumin—a key marker of kidney damage—compared to those receiving traditional care, indicating healthier kidneys.
The research, led by Dr. Jamie Dwyer at the University of Utah Health, highlights the dual benefits of the drug. On average, baxdrostat lowered blood pressure by approximately 8.1 mm Hg more than standard treatments. This is corroborated by a larger, almost 800-patient trial where similar blood pressure reductions were observed, establishing baxdrostat as a potential game-changer in hypertension management.
Unlike conventional medications, baxdrostat operates through a unique mechanism by reducing the production of aldosterone, a hormone that raises blood pressure by increasing salt retention and contributes to kidney inflammation and scarring. Up to a quarter of people with resistant high blood pressure have elevated aldosterone levels, making baxdrostat particularly effective for this demographic.
Given its ability to target the hormone source directly, baxdrostat offers hope not only for better blood pressure control but also for protecting kidney function, especially for the one in seven adults in the U.S. living with chronic kidney disease. Currently, phase III trials are underway to further verify its benefits. The promising results suggest that baxdrostat could revolutionize treatment strategies for resistant hypertension and kidney health, potentially transforming patient outcomes.
Source: https://medicalxpress.com/news/2025-09-drug-lowers-treatment-resistant-high.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Understanding the Differences Between Hot Sweat and Cold Sweat
Learn the key differences between hot and cold sweat, their causes, and what they reveal about your health or emotional state. This guide explains how body temperature regulation and emotional responses trigger distinct sweating types.
Influenza Hospitalization Rates Reach New Highs in the 2024-2025 Flu Season
The 2024-2025 flu season has seen unprecedented influenza-related hospitalizations, with rates significantly higher than previous years, especially among seniors. Early vaccination and prompt antiviral treatment are vital.
Only 36.4% of U.S. Adults Are Free of Cardiovascular Disease Risk Factors in Recent Years
A recent study shows that only 36.4% of U.S. adults had no cardiovascular disease risk factors from August 2021 to 2023, highlighting ongoing challenges in cardiovascular health and prevention.
Blood Plasma Highlights Common Biological Pathways in Neurodegenerative Disorders
A landmark study identifies common protein pathways in Alzheimer's, Parkinson's, and FTD, paving the way for earlier diagnosis and new treatment strategies in neurodegenerative diseases.